| INTRODUC TI ON
Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, accounting for more than 700 000 deaths annually worldwide. 1, 2 Hepatitis B and C, alcohol and aflatoxin have been identified as major risk factors for HCC. 3, 4 Despite progress in surgical techniques, chemotherapy and radiotherapy in the treatment of HCC, the 5-year relative survival rate for patients with HCC is only 7%, largely due to tumour recurrence and metastases. 5, 6 The paucity of effective and well-tolerated treatments for advanced HCC highlights the need for new therapeutic approaches. In the past decade, systemic administration of a multikinase inhibitor, sorafenib, was approved for clinical use for patients with advanced HCC. 7 However, beneficial effects of sorafenib were observed in only approximately 30% of patients, and acquired drug resistance often develops within 6 months. [8] [9] [10] [11] Thus, there is an urgent need to develop novel and specific HCCtargeting drugs.
Histone deacetylases (HDACs) are a class of enzymes that remove acetyl groups from specific lysine residues on core histones, thereby regulating gene transcription via histone and chro- . 15 Although HDACis have been shown to be effective in the treatment of many other types of cancer, their efficacy against HCC is still largely unknown. 16 In mammals, a total of 18 HDAC homologues have been identified, and they are subdivided into classes I, IIa, IIb, III and IV. The functions of HDAC isoforms are not yet fully understood. Some HDAC isoforms have been found to be associated with specific diseases, such as cancer and neurodegenerative diseases. 12, 17 Most early HDACis, such as SAHA, TSA, VPA and butyrate, are global
HDACis. 18 Their effects in cancer therapy are unpredictable, and they have shown different side effects as well. 16 Therefore, selective
HDACis are highly desirable for achieving a better understanding of the biological functions of different HDAC isoforms and, more importantly, for the development of agents with more precise therapeutic effects and fewer side effects.
HDAC1 and HDAC2, the 2 members of the class I HDAC family, are ubiquitously expressed in organs and tissues, including the liver. 19 HDAC1 and HDAC2 typically associate with co-repressors to form transcriptional co-repressor complexes. 12 They are also required for chromatin condensation, spindle formation and correct separation during cell mitosis and deregulation of HDAC1/2 can lead to abnormal karyokinesis. 20 Both HDAC1 and HDAC2 play an essential role in mouse growth and development, and they play redundant roles in the regulation of cell proliferation. 20 
| MATERIAL S AND ME THODS

| Reagents and antibodies
The HDAC1 inhibitor CI994 (Tacedinaline), the HDAC2 inhibitor Santacruzamate A (CAY10683), and the HDAC1 and HDAC2 inhibitor Romidepsin (FK228) were purchased from Selleck (Shanghai, China). were purchased from Abcam (Cambridge, UK).
| Cell culture
The human HCC cell lines HepG2, Huh7, and MHCC97H were cultured in DMEM supplemented with 10% foetal bovine serum, streptomycin (100 mg/mL) and penicillin (100 U/mL). The normal liver cell line L02 was cultured in RPMI 1640 medium with 10% foetal bovine serum, streptomycin (100 mg/mL) and penicillin (100 U/mL). Cultured cells were maintained at 37°C and 5% CO 2 in a humid environment and passaged when the confluency reached 80%. Different concentrations of inhibitors were diluted in DMSO based on their IC50 and added 2-3 days before the cells were processed for further analyses.
| Cell proliferation assay
Two HCC cell lines were treated with different HDACis for the indicated time periods, and the cells were then harvested for cell proliferation analysis using a cell counting kit-8 (Biotool, Shanghai, China)
according to the manufacturer's instructions. 
| Western blot analysis
| Cell cycle analysis and apoptosis assay
Cells were seeded at a density of 1.0 × 10 6 cells/mL, and the cell cycle distribution was analysed by flow cytometry after treatment with different inhibitors. After washing twice with PBS, the cells were harvested and collected by centrifugation, followed by fixation in ice-cold 70% ethanol at −20°C overnight. Then, the cells were collected and stained with 100 μL of PI staining solution for 30 minutes in the dark, followed by cell cycle analysis. The cells were washed with PBS, detached with trypsin, and harvested.
Apoptotic cells were detected with an Annexin-V-FITC Apoptosis
Detection Kit (Biotool, Shanghai, China), according to the manufacturer's instructions.
| Quantitative real-time PCR
Primers were designed using Primer 3 online software and synthesized by HuaDa (Shanghai, China) ( 
| Chromatin immunoprecipitation (ChIP) assay
The distribution of transcription factors associated with the 
TA B L E 1 The qPCR primers used in this project
Primer Forword Reverse
primers specific to the promoter. The primer pairs used to amplify the p19 INK4d and p21 Waf1/Cip1 promoters were as follows: p19 INK4d ,
forward: 5′-TTG AAA ACC GAA AAC CCC GC-3′, reverse: 5′-CCC GAA CGC AAC TGA TTT GT-3′; p21 Waf1/Cip1 , forward: 5′-TTG TTG GGG TGT CTA GGT GC-3′, reverse: 5′-ACT CTG GCA GGC AAG GAT TT -3′.
| Xenograft studies
Four-week-old nude mice were bred in house and used for animal experiments. The animal study and experimental protocols were 
| Haematoxylin-eosin (H&E) staining
H&E staining was used to observe histopathological alterations of the subcutaneously implanted tumours in nude mice. The tissue was fixed with 4% paraformaldehyde, dehydrated using a graded ethanol series, embedded in paraffin (Thermo Fisher Scientific Inc., USA), and cut into sections (5 μM). The sections were subjected to conventional dewaxing and were stained with H&E for 10 minutes.
After washing in running water for 15 minutes, a 1% alcohol solution was used for differentiation. The sections were washed, dehydrated using a graded ethanol series, and re-dyed with haematoxylin for 2 minutes. After dehydration, clearing and sealing with resinene, an Olympus CX31 microscope was used to observe pathological changes in the tissue.
| Immunohistochemistry
Four-μm-thick paraffin sections of xenograft HCC tumour tissues were prepared. After the slides were incubated in xylene and a graded ethanol series, antigen retrieval was performed, and the slides were then blocked with hydrogen peroxide. The sections were incubated with a primary antibody against Ki-67 at 4°C overnight, and then a biotinylated secondary antibody and ABC Peroxidase
Staining Kit (Thermo Fisher Scientific, USA) were used. After that, the sections were counterstained with haematoxylin.
| Cell transfection
Cells were plated at between 40% and 60% confluence 1 day 
| Statistical analysis
Statistical analysis was performed using spss 13.0 software for Windows. Significant differences were calculated using the t test or 1-way ANOVA for paired samples. P ≤ .05 was regarded as significant and P ≤ .01 as highly significant.
| RE SULTS
| HDAC1 and 2 expression predicted HCC patient survival
To clarify the function of HDACs during the carcinogenesis of HCC, we analysed the variation in and prognostic value of HDAC1, 2 and 3 expression levels in an independent cohort of 373 HCC (including 50 paired tumour and normal liver tis- 
| Selective inhibition of HDAC1 and 2 led to changes in cell morphology, growth and cell cycle progression
Based on the clinical data indicating that HDAC1/2 are highly expressed in HCC, we hypothesized that HDAC1 and 2 might be es- Figure S1A) . This effect appears to be specific to HDAC1, as it was not observed in cells treated with the HDAC2 inhibitor (CAY10683). However, both CI994 and CAY10683
induced an increase in H4K12 acetylation. The HDAC2 inhibitor CAY10683 did not increase the acetylation level of any H3 site but specifically induced H4K12 and H4K5 acetylation ( Figure S1B ). The Bax/Bcl-2 ratio was significantly higher in FK228-and CI994+CAY10683-treated groups than in the control, CI994, CAY10683 and SAHA groups. GAPDH expression served as an internal control
We evaluated the effect of the HDACis on cell morphology, growth and the cell cycle. In L02 cell, all of the 4 HDACis did not induce cell morphological change compared with control ( Figure S2A ). In HCC cells, treatment with either CI994 or CAY10683 did not induce cell morphological changes compared with control cells. By contrast, treatment with either FK228 or SAHA had a significant effect on cell morphology.
Interestingly, treatment with CI994+CAY10683 had a similar effect as treatment with FK228 and SAHA (Figure 2A) . A CCK-8 assay further
showed that CI994 or CAY10683 treatment did not affect cell proliferation. However, CI994+CAY10683-and FK228-treated cells showed obvious growth inhibition. In addition, cells treated with SAHA showed a limited effect for cell proliferation ( Figure 2B ). As FK228-and CI994+CAY10683-treated HCC cells showed growth inhibition, we next sought to analyse the cell cycle distribution. As shown in Figure 2C , there were few cell cycle differences between control and CI994/CAY10683-treated cells. By contrast,
F I G U R E 4
FK228-treated cells showed a reduced percentage of cells in S
phase and a corresponding increase in G1 phase. Moreover, the CI994 + CAY10683 group also showed a reduced percentage of cells in S phase ( Figure 2C ). However, both FK228 and CI994 + CAY10683
showed a less effect on L02 cell ( Figure S2B ). We also examined the protein levels of cell cycle markers in cells treated with different
HDACis. The expression of cyclin D1, CDK4 and CDK6, all of which appear in the early G1 phase, showed same levels in L02 cell but was significantly downregulated after CI994+CAY10683 or FK228 treatment in HepG2 and Huh7 cells ( Figure S2C ; Figure 2D ). In addition, CDK2 and cyclin B1, which are specifically expressed at the G1/S or G2/M checkpoint, were markedly reduced in HepG2 cells treated with both HDAC1 and 2 inhibitors ( Figure 2D ). These observations correlate well with the slow proliferation phenotype observed in cells treated with both HDAC1 and 2 inhibitors.
| Selective inhibition of HDAC1 and 2 led to cell apoptosis
To investigate the effects of HDAC inhibitors on cell apoptosis, we performed an Annexin-V staining followed by flow cytometric anal- The above data suggest that CI994 + CAY10683 and FK228 inhibit HCC growth by upregulating the acetylation levels of specific histone lysine sites that are targets of HDAC1 and 2. To test this idea, we ex- 
| D ISCUSS I ON
Though HDAC activity has been reported to be upregulated in many ity. 34 Indeed, in the current study, we found that selective inhibition of F I G U R E 6 Transcriptional HDAC1/2 inhibition leads to cell cycle blockage and apoptosis in liver cancer cells. (A) qRT-PCR and Western blot analyses of HDAC1 and HDAC2 were performed after siRNA transfection. Figure 7) . Therefore, further studies in preclinical models and in clinical settings, alone and in combination with other drugs, such as sorafenib, are now required to determine whether these drugs are candidates for the treatment of HCC patients.
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